FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a bispecific antigen-binding molecule specifically binding to GPRC5D and CD3. Said molecule contains HCDR1-3 with SEQ ID NO: 83, 85 and 86, LCDR1-3 with SEQ ID NO: 87, 88 and 89, HCDR1-3 with SEQ ID NO: 98, 99, 100 and LCDR1-3 with SEQ ID NO: 101, 102, 103. Present invention also relates to a polynucleotide encoding said molecule, an expression vector, a host cell, a method for producing such a molecule, as well as to a pharmaceutical composition containing same.
EFFECT: present invention provides bispecific antigen-binding molecules with specificity to both GPRC5D and CD3.
26 cl, 25 dwg, 19 tbl, 22 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TUMOR-TARGETING AGONIST CD28 ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2837821C1 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| ANTIBODIES BINDING TO GPRC5D | 2019 |
|
RU2797268C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2832669C2 |
| PROTEASE-ACTIVATED T-CELL BINDING BISPECIFIC MOLECULES | 2017 |
|
RU2830288C2 |
| IMPROVED ANTIGEN-BINDING RECEPTORS | 2018 |
|
RU2825816C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
